The GLP-1 Moment…
and Opportunity
Kantar resources, research and consulting
Our offerings
Fill out the form on the right to dig deeper into each offering
GLP-1 Syndicated Study
Digital Trends Pulse
U.S. MONITOR Quick Dives
Foresight Co-Lab: Beyond Ozempic™
A multi-client, 3-month consulting project to explore the potential scenarios of anti-obesity medications over the next three to five years. Starting with a summit and concluding with a briefing. Optional planning workshop also offered.
Other content
Kantar’s Retail Sound Bites
Episode 54: Balancing Act: GLP-1 Breakthroughs and the Impact on CPGs
In episode 54 of Kantar’s Retail Sound Bites, Barry Thomas, senior retail thought leader, and Rachel Dalton, head of retail insights, discuss the rise of GLP-1 weight-loss drugs and the forecasted implications on the food and beverage industries with Leigh O’Donnell, head of shopper and category insights, and Patricia Gregory, global analytics lead, at Kantar.
Episode 48: The GLP-1 Revolution: Retail Health Unveiled with Leslie Thomas and Cathy Watkins
GLP-1 drugs are gaining popularity as an innovative solution to weight loss. With almost 43% of the US population being obese, this presents a strategic opportunity for the healthcare industry. Only 20% of Semaglutide users experience side effects, and the significant advertising spending by Rx manufacturers is driving demand for this new class of weight loss drugs.
Webinar: Managing the Weight—GLP-1s and What’s to Come
GLP-1 medications have taken the healthcare industry – and pop culture – by storm and have the potential to reshape the eating and shopping habits of consumers everywhere. As demand grows, manufacturers and retailers of food, beverages, and health-adjacent categories need to keep their eyes on emerging and shifting consumer trends and how they will shape the future for brands.
Please fill out the form on the right. A Kantar account person will follow-up.